For the HBB gene, one amplicon was designed to target variants associated with thalassaemias, sickle cell anaemia (HbS), HbC, HbE, as well as a variety of other haemoglobinopathies, and the average coverage for the HBB amplicon was 2195-fold. This evidence concerns the gene KRT88P and sickle cell disease.